Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bce595c861dba361078ba893e4713be |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 |
filingDate |
2009-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4887f76929a46ce207244bacad5e0506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70d897e12de2dc9224ecd2a96d20826f |
publicationDate |
2011-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20110050583-A |
titleOfInvention |
Induction of Tumor Hypoxia Status for Cancer Treatment |
abstract |
Methods and compositions are provided for enhancing the ability of low oxygen-activated bioreducers to kill tumor cells in solid tumors. Local regions of the low oxygen state are created in the tumor, or within the region containing the tumor, which enhances the activation of the low oxygen-activated bioreducing agent (eg tyrapazamin) in the local region. The activated low oxygen-activated bioreducer kills tumor cells in the low oxygen region by promoting DNA strand breakage in the tumor cells. Since the activity is localized, side effects typically occurring as a result of systemic administration of bioreducing agents are reduced. |
priorityDate |
2008-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |